3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:千円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 10,274,773 | 12,032,136 |
受取手形、売掛金及び契約資産 | 5,778,872 | 6,643,088 |
有価証券 | 336,724 | - |
棚卸資産 | 12,373,178 | 12,618,001 |
その他 | 2,130,226 | 1,777,229 |
貸倒引当金 | △56,062 | △130,608 |
流動資産合計 | 30,837,713 | 32,939,848 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 26,568,142 | 38,910,224 |
減価償却累計額 | △15,881,201 | △16,814,034 |
建物及び構築物(純額) | 10,686,940 | 22,096,190 |
機械装置及び運搬具 | 1,363,822 | 1,608,130 |
減価償却累計額 | △815,008 | △894,145 |
機械装置及び運搬具(純額) | 548,813 | 713,984 |
工具、器具及び備品 | 7,457,919 | 10,332,750 |
減価償却累計額 | △5,450,145 | △6,127,460 |
工具、器具及び備品(純額) | 2,007,773 | 4,205,289 |
土地 | 3,959,041 | 4,546,836 |
リース資産 | 2,367,780 | 2,456,953 |
減価償却累計額 | △1,110,948 | △1,130,307 |
リース資産(純額) | 1,256,832 | 1,326,645 |
建設仮勘定 | 7,898,265 | 1,943,570 |
有形固定資産合計 | 26,357,666 | 34,832,518 |
無形固定資産 | | |
のれん | 1,934,419 | 1,884,230 |
その他 | 224,879 | 219,125 |
無形固定資産合計 | 2,159,298 | 2,103,356 |
投資その他の資産 | | |
投資有価証券 | 15,235,711 | 19,762,231 |
長期貸付金 | 32,819 | 35,046 |
繰延税金資産 | 989,998 | 2,036,947 |
その他 | 703,085 | 883,095 |
貸倒引当金 | △13,947 | △176,535 |
投資その他の資産合計 | 16,947,667 | 22,540,785 |
固定資産合計 | 45,464,633 | 59,476,659 |
資産合計 | 76,302,347 | 92,416,508 |
| | (単位:千円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
負債の部 | | |
流動負債 | | |
支払手形及び買掛金 | 460,527 | 460,937 |
短期借入金 | 7,826,167 | 11,777,811 |
未払法人税等 | 1,701,128 | 2,217,925 |
前受金 | 9,542,361 | 10,941,641 |
その他 | 4,037,708 | 3,857,829 |
流動負債合計 | 23,567,894 | 29,256,146 |
固定負債 | | |
長期借入金 | 18,147,876 | 22,271,126 |
リース債務 | 212,815 | 425,099 |
繰延税金負債 | 84,939 | 235,533 |
その他 | 128,185 | 143,011 |
固定負債合計 | 18,573,818 | 23,074,771 |
負債合計 | 42,141,712 | 52,330,917 |
純資産の部 | | |
株主資本 | | |
資本金 | 9,679,070 | 9,679,070 |
資本剰余金 | 2,358,493 | 2,358,493 |
利益剰余金 | 17,215,849 | 20,087,636 |
自己株式 | △420 | △745 |
株主資本合計 | 29,252,993 | 32,124,455 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 3,644,434 | 6,031,759 |
為替換算調整勘定 | 1,216,991 | 1,866,521 |
その他の包括利益累計額合計 | 4,861,426 | 7,898,281 |
非支配株主持分 | 46,215 | 62,854 |
純資産合計 | 34,160,635 | 40,085,590 |
負債純資産合計 | 76,302,347 | 92,416,508 |
E0538523950株式会社新日本科学Shin Nippon Biomedical Laboratories, Ltd通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse239502025-03-31tse-acedjpfr-23950:USAssetManagementReportableSegmentMember239502024-04-012025-03-31tse-acedjpfr-23950:USAssetManagementReportableSegmentMember239502024-03-31tse-acedjpfr-23950:USAssetManagementReportableSegmentMember239502023-04-012024-03-31tse-acedjpfr-23950:USAssetManagementReportableSegmentMember239502025-03-31tse-acedjpfr-23950:USAssetManagementReportableSegment2Member239502024-04-012025-03-31tse-acedjpfr-23950:USAssetManagementReportableSegment2Member239502024-03-31tse-acedjpfr-23950:USAssetManagementReportableSegment2Member239502023-04-012024-03-31tse-acedjpfr-23950:USAssetManagementReportableSegment2Member239502023-04-012024-03-31tse-acedjpfr-23950:TranslationalResearchMember239502023-04-012024-03-31tse-acedjpfr-23950:MedipolisMember239502025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember239502025-03-31tse-acedjpfr-23950:CROMember239502025-03-31jpcrp_cor:ReconcilingItemsMember239502024-04-012025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember239502024-04-012025-03-31tse-acedjpfr-23950:CROMember239502024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember239502024-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember239502024-03-31tse-acedjpfr-23950:CROMember239502024-03-31jpcrp_cor:ReconcilingItemsMember239502023-04-012024-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember239502023-04-012024-03-31tse-acedjpfr-23950:CROMember239502023-04-012024-03-31jpcrp_cor:ReconcilingItemsMember239502025-03-31jpcrp_cor:ReportableSegmentsMember239502025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember239502025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember239502024-04-012025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember239502024-04-012025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember239502024-03-31jpcrp_cor:ReportableSegmentsMember239502024-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember239502024-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember239502023-04-012024-03-31jpcrp_cor:ReportableSegmentsMember239502023-04-012024-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember239502023-04-012024-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember239502025-03-31tse-acedjpfr-23950:CROServicesMember239502025-03-31tse-acedjpfr-23950:TranslationalResearchMember239502025-03-31tse-acedjpfr-23950:MedipolisMember239502024-04-012025-03-31tse-acedjpfr-23950:CROServicesMember239502024-04-012025-03-31tse-acedjpfr-23950:TranslationalResearchMember239502024-04-012025-03-31tse-acedjpfr-23950:MedipolisMember239502024-03-31tse-acedjpfr-23950:CROServicesMember239502024-03-31tse-acedjpfr-23950:TranslationalResearchMember239502024-03-31tse-acedjpfr-23950:MedipolisMember239502023-04-012024-03-31tse-acedjpfr-23950:CROServicesMember239502024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember239502023-04-012024-03-31jppfs_cor:CapitalStockMember239502023-04-012024-03-31jppfs_cor:CapitalSurplusMember239502024-03-31jppfs_cor:CapitalSurplusMember239502024-03-31jppfs_cor:RetainedEarningsMember239502024-03-31jppfs_cor:TreasuryStockMember239502024-03-31jppfs_cor:ShareholdersEquityMember239502024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember239502024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember239502024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember239502024-03-31jppfs_cor:NonControllingInterestsMember239502023-04-012024-03-31jppfs_cor:TreasuryStockMember239502023-03-31jppfs_cor:CapitalStockMember239502023-03-31jppfs_cor:CapitalSurplusMember239502025-03-31jppfs_cor:ShareholdersEquityMember239502025-03-31jppfs_cor:CapitalStockMember239502025-03-31jppfs_cor:CapitalSurplusMember239502025-03-31jppfs_cor:RetainedEarningsMember239502025-03-31jppfs_cor:TreasuryStockMember239502025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember239502025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember239502024-04-012025-03-31jppfs_cor:RetainedEarningsMember239502024-04-012025-03-31jppfs_cor:TreasuryStockMember239502024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember239502024-04-012025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember239502024-04-012025-03-31jppfs_cor:NonControllingInterestsMember239502023-03-31jppfs_cor:TreasuryStockMember239502023-03-31jppfs_cor:ShareholdersEquityMember239502023-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember239502023-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember239502023-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember239502023-03-31jppfs_cor:NonControllingInterestsMember239502023-04-012024-03-31jppfs_cor:RetainedEarningsMember239502023-04-012024-03-31jppfs_cor:ShareholdersEquityMember239502023-04-012024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember239502023-04-012024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember239502023-04-012024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember239502024-03-31jppfs_cor:CapitalStockMember239502023-03-31jppfs_cor:RetainedEarningsMember239502024-04-012025-03-31jppfs_cor:ShareholdersEquityMember239502025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember239502025-03-31jppfs_cor:NonControllingInterestsMember239502024-04-012025-03-31jppfs_cor:CapitalStockMember239502024-04-012025-03-31jppfs_cor:CapitalSurplusMember239502024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember239502023-04-012024-03-31jppfs_cor:NonControllingInterestsMember239502025-05-08239502025-03-31239502024-04-012025-03-31239502024-03-31239502023-04-012024-03-31239502023-03-31iso4217:JPYxbrli:pure